Overall survival benefit and safety profile of Radium-223 Chloride (Alfaradin), a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases - Parker, C; Heinrich, D; O’Sullivan, J M (Annual Meeting of the GU ASCO)
2.–4.2.1012